LCN2 and acute kidney injury: Improved recognition and awareness of AKI as a clinical complication associated with both short- and long-term morbidity and mortality and expanded access to diagnostic tools, including urinalysis, creatinine, and novel biomarkers will support early diagnosis, such as cystatin C [73], saliva urea nitrogen, urine NGAL/lipocalin-2 [74], or miRNAs [75] (Figure 2).